Aesthetic plastic surgery · 2018
Correction of Tear Trough Deformity Using Autologous Fibroblast Combined with Keratin: New Soft Tissue Filler.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xing Wenshan, Zhang Chen, Zhang Jiao, Zhang Qingguo
Аннотация
OBJECTIVE: To evaluate the effectiveness and safety of autologous fibroblasts combined with keratin gel for tear trough deformity rectification as injectable soft tissue filler.
MATERIALS AND METHODS: The new injectable soft tissue filler was derived from autologous fibroblasts and keratin gel. A total of 35 patients received treatment of this filler injection for tear trough deformity rectification. All the patients were followed up, and the clinical features including photographs and satisfaction were collected and assessed at 1, 3, 6, 12 and 24 months after injection. The efficacy of each patient was evaluated independently by blinded evaluators at different time points. All patients consented to publish identifiable photographs in this study.
RESULTS: Tear trough deformity was improved even at 18-24 months post-injection. No severe adverse effects were observed resulting from the filler injection.
CONCLUSION: Combination of autologous fibroblasts and keratin is efficient and safe for correction of the tear trough deformity with long-term satisfaction and desirable result.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
MATERIALS AND METHODS: The new injectable soft tissue filler was derived from autologous fibroblasts and keratin gel. A total of 35 patients received treatment of this filler injection for tear trough deformity rectification. All the patients were followed up, and the clinical features including photographs and satisfaction were collected and assessed at 1, 3, 6, 12 and 24 months after injection. The efficacy of each patient was evaluated independently by blinded evaluators at different time points. All patients consented to publish identifiable photographs in this study.
RESULTS: Tear trough deformity was improved even at 18-24 months post-injection. No severe adverse effects were observed resulting from the filler injection.
CONCLUSION: Combination of autologous fibroblasts and keratin is efficient and safe for correction of the tear trough deformity with long-term satisfaction and desirable result.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .